Rather than portraying psoriasis as a direct causal agent in CVD progression (e.g., via the “psoriatic march” of IL-17-driven endothelial dysfunction), we posit that the two conditions often co-occur due to shared upstream causes. The gene discussed is IL17A; the disease is endothelial dysfunction.